ArticleAsian Pacific journal of cancer prevention : APJCP2026
Analysis of In-Vivo Dose Measurement of Urethra Using Array MOSFET Detectors and TPS-Calculated Dose in High-Dose-Rate Interstitial Brachytherapy in Gynaecological Malignancies.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe urinary sub-structures, which lie in close proximity to the target, are often not contoured or evaluated during cervical cancer brachytherapy planning. This study aims to investigate the in vivo urethral dose during High-Dose-Rate Interstitial Brachytherapy applications using an array of Metal-Oxide-Semiconductor Field-Effect-Transistor detectors, and to compare the urethral dose recorded during brachytherapy planning with that calculated by the treatment planning system.
methodsTwenty patients with cancer of the cervix, vagina, or vault, from Stage IB to Stage IV, who were treated with external beam radiotherapy (EBRT) and interstitial brachytherapy, were included in the study. The high-risk clinical target volume and organs at risk, such as the urinary bladder, rectum, sigmoid colon, urethra, and periurethra, were delineated. The commercially available linear array MOSFET detector, with each detector and its reader module, was characterized and used in this study. The detector channel was inserted into the Foley's catheter until it reached the neck of the bladder.
resultsThe maximum and mean doses received by the urethra were 486.32 ± 105.88 cGy and 246.73 ± 101.43 cGy per fraction, respectively, for the prescription dose of 700 cGy/fraction. The maximum dose received by the periurethra per fraction of brachytherapy was 697.43 ± 165.26 cGy, and the cumulative dose, in terms of Equivalent Dose at 200 cGy (EQD2) received by the periurethral region, including the EBRT dose, was found to be 13,406.1 ± 2,909.17 cGy. The urethral doses calculated by the Treatment Planning System (TPS) were compared with the doses measured by the detector per fraction of brachytherapy during treatment.
conclusionThe urethral doses calculated by the Treatment Planning System (TPS) were comparable to the doses measured by the MOSFET detector. Urethral dose measurement using an array of MOSFET detectors in patients treated with the Interstitial Brachytherapy (ISBT) technique proved its suitability and ease for measuring urethral dose. A good correlation was observed between the MOSFET-measured dose and the TPS-calculated dose, with a P-value > 0.05.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.